Trigen makes two appointments
This article was originally published in Scrip
Executive Summary
Trigen (Germany), a drug development company developing biologics for use in antithrombotic therapy, has appointed Dr Ayad Abdul-Ahad chief executive officer and Dr Norbert Bender chief medical officer. Dr Abdul-Ahad joins from Biogen Idec, where he served as vice-president and head of international medical affairs; he has also worked at Berlex Laboratories, AstraZeneca, SmithKline Beecham and Serono. Dr Bender has more than 10 years' experience as a medical doctor and has more than 15 years' experience in pharmaceutical companies, having previously worked at Hoescht, BASF Pharma Knoll, Cardion and The Vaccines Company.